JP3993746B2 - 腫瘍性細胞成長阻害のための組成物及び方法 - Google Patents

腫瘍性細胞成長阻害のための組成物及び方法 Download PDF

Info

Publication number
JP3993746B2
JP3993746B2 JP2000589692A JP2000589692A JP3993746B2 JP 3993746 B2 JP3993746 B2 JP 3993746B2 JP 2000589692 A JP2000589692 A JP 2000589692A JP 2000589692 A JP2000589692 A JP 2000589692A JP 3993746 B2 JP3993746 B2 JP 3993746B2
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
sequence identity
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000589692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529317A (ja
JP2003529317A5 (cg-RX-API-DMAC7.html
Inventor
アシュケナジ,アヴィ,ジェイ.
ゴダード,オードリー
ジェイ. ゴドスキー,ポール
ガーニー,オースティン,エル.
マースタース,スコット,エー.
ネイピエール,メアリー,エー.
ピッティ,ロバート,エム.
アイ. ウッド,ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003529317A publication Critical patent/JP2003529317A/ja
Publication of JP2003529317A5 publication Critical patent/JP2003529317A5/ja
Application granted granted Critical
Publication of JP3993746B2 publication Critical patent/JP3993746B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000589692A 1998-12-22 1999-12-02 腫瘍性細胞成長阻害のための組成物及び方法 Expired - Fee Related JP3993746B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11329698P 1998-12-22 1998-12-22
US60/113,296 1998-12-22
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US9905028 1999-03-08
US13023299P 1999-04-21 1999-04-21
US60/130,232 1999-04-21
US13144599P 1999-04-28 1999-04-28
US60/131,445 1999-04-28
US13428799P 1999-05-14 1999-05-14
US60/134,287 1999-05-14
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
US9921547 1999-09-15
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
US9921090 1999-09-15
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/028565 WO2000037638A2 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005066569A Division JP4037876B2 (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法
JP2005066570A Division JP2005237383A (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2003529317A JP2003529317A (ja) 2003-10-07
JP2003529317A5 JP2003529317A5 (cg-RX-API-DMAC7.html) 2004-12-24
JP3993746B2 true JP3993746B2 (ja) 2007-10-17

Family

ID=27557838

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000589692A Expired - Fee Related JP3993746B2 (ja) 1998-12-22 1999-12-02 腫瘍性細胞成長阻害のための組成物及び方法
JP2005066569A Expired - Lifetime JP4037876B2 (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法
JP2005066570A Withdrawn JP2005237383A (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法
JP2007138468A Pending JP2007222180A (ja) 1998-12-22 2007-05-24 腫瘍性細胞成長阻害のための組成物及び方法
JP2007138469A Pending JP2007291116A (ja) 1998-12-22 2007-05-24 腫瘍性細胞成長阻害のための組成物及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2005066569A Expired - Lifetime JP4037876B2 (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法
JP2005066570A Withdrawn JP2005237383A (ja) 1998-12-22 2005-03-10 腫瘍性細胞成長阻害のための組成物及び方法
JP2007138468A Pending JP2007222180A (ja) 1998-12-22 2007-05-24 腫瘍性細胞成長阻害のための組成物及び方法
JP2007138469A Pending JP2007291116A (ja) 1998-12-22 2007-05-24 腫瘍性細胞成長阻害のための組成物及び方法

Country Status (13)

Country Link
EP (1) EP1141284A2 (cg-RX-API-DMAC7.html)
JP (5) JP3993746B2 (cg-RX-API-DMAC7.html)
KR (1) KR100499600B1 (cg-RX-API-DMAC7.html)
AT (2) ATE353339T1 (cg-RX-API-DMAC7.html)
AU (1) AU768230B2 (cg-RX-API-DMAC7.html)
CA (1) CA2353799A1 (cg-RX-API-DMAC7.html)
DE (2) DE69940964D1 (cg-RX-API-DMAC7.html)
DK (1) DK1484338T3 (cg-RX-API-DMAC7.html)
ES (2) ES2327785T3 (cg-RX-API-DMAC7.html)
IL (3) IL143031A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01006330A (cg-RX-API-DMAC7.html)
PT (1) PT1484338E (cg-RX-API-DMAC7.html)
WO (1) WO2000037638A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808890B2 (en) 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU763012B2 (en) 1997-11-22 2003-07-10 Arca Biopharma, Inc. A novel EGF motif protein obtained from a cDNA library of fetal liver-spleen
NZ528700A (en) * 1998-04-08 2005-02-25 Genentech Inc Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
JP2003531811A (ja) * 1999-03-08 2003-10-28 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
ATE368110T1 (de) * 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
HUP0203408A3 (en) * 1999-12-09 2005-01-28 Sankyo Co Method of testing remedy or preventive for hyperlipemia
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
ES2341608T3 (es) 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
CA2391438A1 (en) * 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
HRP20161580T1 (hr) 2008-05-06 2016-12-30 Genentech, Inc. CRIg-VARIJANTE S RAZVIJENIM AFINITETOM
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体コンジュゲート及びその使用
CN114835774B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽msl及其在预防或治疗癌症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5028099A (en) * 1990-08-08 1991-07-02 Bertucco Leonard J Trash recycling container
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
JP7039446B2 (ja) * 2018-11-29 2022-03-22 株式会社東芝 電子装置

Also Published As

Publication number Publication date
WO2000037638A2 (en) 2000-06-29
DE69940964D1 (de) 2009-07-16
ES2327785T3 (es) 2009-11-03
JP2003529317A (ja) 2003-10-07
DE69935085T2 (de) 2007-08-23
CA2353799A1 (en) 2000-06-29
ATE353339T1 (de) 2007-02-15
ATE432987T1 (de) 2009-06-15
JP2007291116A (ja) 2007-11-08
JP4037876B2 (ja) 2008-01-23
JP2005237383A (ja) 2005-09-08
DK1484338T3 (da) 2007-06-11
ES2281704T3 (es) 2007-10-01
MXPA01006330A (es) 2002-07-02
IL186153A0 (en) 2008-01-20
WO2000037638A3 (en) 2000-11-09
JP2005245451A (ja) 2005-09-15
DE69935085D1 (de) 2007-03-22
AU768230B2 (en) 2003-12-04
AU1749900A (en) 2000-07-12
KR20010084882A (ko) 2001-09-06
IL143031A0 (en) 2002-04-21
KR100499600B1 (ko) 2005-07-07
JP2007222180A (ja) 2007-09-06
PT1484338E (pt) 2007-05-31
IL186154A0 (en) 2008-01-20
EP1141284A2 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
JP4037876B2 (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP4074645B2 (ja) 腫瘍細胞成長阻害のための組成物及び方法
JP5897300B2 (ja) 腫瘍治療のための組成物と方法
JP2004000008A (ja) 新規なポリペプチド及びそれをコードする核酸
JP4280444B2 (ja) 腫瘍性細胞成長阻害のための組成物及び方法
US20020010137A1 (en) Methods and compositions for inhibiting neoplastic cell growth
JP2002531092A (ja) 腫瘍性細胞成長阻害のための組成物及び方法
EP1121439B1 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1820859B9 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1466977A1 (en) Methods and compositions for inhibiting neoplastic cell growth
JP2005518820A (ja) Gdnfrと配列類似性を有する新規ポリペプチド及びこれをコードする核酸
JP2007238619A (ja) 腫瘍性細胞成長阻害のための組成物及び方法
AU2003257515B2 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1518930A2 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1867719A2 (en) Methods and compositions for inhibiting neoplastic cell growth

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20041214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070727

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100803

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110803

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees